Cytokinetics, Incorporated (CYTK) Stock

NASDAQ: CYTKBiopharmaceutical company developing muscle activators as potential treatments for neuromuscular and other diseases.

Cytokinetics stock price chart

CYTK stock quote & key statistics

CYTK stock performance

Cytokinetics shares are down 16.2% over the past year and trade near the bottom of their 52-week range of $53.55–$88.31. The company has a market cap of $7.82B.

CYTK financial performance

In fiscal 2025, Cytokinetics' revenue was $88.0M, an increase of 376.6% from $18.5M the year before. The company reported a net loss of $785.0M, compared with a net loss of $589.5M the year before, and the loss per share was $5.52.

CYTK analyst forecast

According to 22 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month price target is $107.39, which is 91.3% above the latest price.

Cytokinetics earnings per share

Income →
Earnings per share

Cytokinetics revenue & net income

Income →
RevenueNet income

Cytokinetics annual financials

Income statement →
Cytokinetics, Incorporated revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2025$88.0M-$785.0M-$5.52
FY2024$18.5M-$589.5M-$5.26
FY2023$7.5M-$526.2M-$5.45
FY2022$94.6M-$389.0M-$3.98
FY2021$70.4M-$215.3M-$2.83

Fiscal year ending December 31. Source: company filings via EODHD.

About Cytokinetics, Incorporated

Cytokinetics, Incorporated is a leading biopharmaceutical company in the late-stage development phase, dedicated to discovering, developing, and commercializing innovative treatments targeting debilitating diseases through muscle activators and inhibitors. Founded in 1997 and headquartered in South San Francisco, California, the company specializes in advancing small molecule drug candidates engineered to impact muscle function and contractility.

The company's diverse pipeline includes omecamtiv mecarbil, a pioneering cardiac myosin activator currently undergoing Phase III clinical trials for heart failure patients. Additionally, Cytokinetics is progressing reldesemtiv, a skeletal muscle troponin activator, through Phase III clinical trials aimed at treating conditions such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

Cytokinetics continues to expand its portfolio with promising candidates like CK-136, a novel cardiac troponin activator in Phase I clinical trials, and aficamten, a cardiac myosin inhibitor also in Phase III clinical trials for symptomatic obstructive hypertrophic cardiomyopathy. Furthermore, the company is advancing CK-3772271, a small molecule cardiac myosin inhibitor currently undergoing Phase I clinical evaluation.

With a strategic alliance with Astellas Pharma Inc., Cytokinetics leverages collaborative efforts to enhance research, development, and commercialization capabilities, underscoring its commitment to pioneering therapies that address significant unmet medical needs in muscle-related diseases. The company remains dedicated to advancing scientific innovation and improving patient outcomes globally.

Cytokinetics stock FAQ

What is the Cytokinetics stock ticker symbol?

Cytokinetics, Incorporated trades on the NASDAQ under the ticker symbol CYTK.

What sector and industry is Cytokinetics in?

Cytokinetics, Incorporated is classified in the Healthcare sector, Biotechnology industry.

How many employees does Cytokinetics have?

Cytokinetics, Incorporated has about 673 full-time employees.

What were Cytokinetics's revenue and earnings last fiscal year?

Cytokinetics reported revenue of $88.0M and net income of -$785.0M in fiscal 2025, with earnings per share of -$5.52. Revenue grew 376.6% from the prior year.

Is Cytokinetics in the S&P MidCap 400?

Yes. Cytokinetics, Incorporated (CYTK) is a component of the S&P MidCap 400, the benchmark index of U.S. mid-cap stocks.

Is Cytokinetics in the Russell 2000?

Yes. Cytokinetics, Incorporated (CYTK) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Cytokinetics go public?

Cytokinetics stock began trading on April 29, 2004.

S&P MidCap 400 Healthcare stocks

All S&P MidCap 400 →